Traded Jan 20 · filed 9 days later
Derivative exercise or conversion — not an open-market buy.
Traded Dec 29, 2025 · Filed Dec 31, 2025
United Therapeutics's PRESIDENT AND COO sold $7.35M of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$7,353,261
Shares × reported transaction price
61 days after results of Oct 29, 2025, 58 days before results of Feb 25, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +3.4% | +1.1% | +2.3% |
| 30 days | −3.6% | +1.5% | −5.1% |
| 90 days | +21.7% | −4.6% | +26.3% |
| 180 days | +11.8% | +8.7% | +3.2% |
Past results only. Not a forecast.
Traded Jan 20 · filed 9 days later
Derivative exercise or conversion — not an open-market buy.
Michael Benkowitz (PRESIDENT AND COO) sold ~$29K of United Therapeutics
Scheduled in advanceMichael Benkowitz (PRESIDENT AND COO) sold ~$170K of United Therapeutics
Scheduled in advance